
Fidson, led by Fidelis Ayebae, declares $1.49 million dividend for shareholders
The payout reflects the pharmaceutical group’s focus on rewarding investors following an impressive financial performance in 2024.
The payout reflects the pharmaceutical group’s focus on rewarding investors following an impressive financial performance in 2024.
Under Ayebae’s guidance, Fidson Healthcare has achieved exceptional financial growth, reporting a significant increase in profits for the 2022 fiscal year.